Anaplastic thyroid cancer: A review of epidemiology, pathogenesis, and treatment

Journal of Oncology

Volumn , Issue , 2011, Pages

  Remick, Scot C ^a   Nagaiah, Govardhanan ^a   Hossain, Akm ^b   Mooney, Colin J ^c   Parmentier, James ^d  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d MGH INSTITUTE OF HEALTH PROFESSIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; CARBOPLATIN; CISPLATIN; COMBRETASTATIN A4 PHOSPHATE; DOCETAXEL; DOXORUBICIN; MITOXANTRONE; PACLITAXEL; SORAFENIB;

ANAPLASTIC THYROID CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL (TOPIC); CYTOREDUCTIVE SURGERY; HUMAN; LOW DRUG DOSE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATHOGENESIS; PROGNOSIS; REVIEW; RISK FACTOR; THYROID CANCER; THYROIDECTOMY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 80052647082     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2011/542358     Document Type: Review

References (108)

1. Ain K. B., Anaplastic thyroid carcinoma: a therapeutic challenge Seminars in Surgical Oncology 1999 16 1 64 69
2. Burke J. P., Hay I. D., Dignan F., Goellner J. R., Achenbach S. J., Oberg A. L., Melton L. J., Long-term trends in thyroid carcinoma: a population-based study in Olmsted County, Minnesota, 19351999 Mayo Clinic Proceedings 2005 80 6 753 758 (Pubitemid 40770362)
3. Demeter J. G., De Jong S. A., Lawrence A. M., Paloyan E., Anaplastic thyroid carcinoma: risk factors and outcome Surgery 1991 110 6 956 963
4. Goldman J. M., Goren E. N., Cohen M. H., Webber B. L., Brennan M. F., Robbins J., Anaplastic thyroid carcinoma: long-term survival after radical surgery Journal of Surgical Oncology 1980 14 4 389 394 (Pubitemid 10003597)
5. Hadar T., Mor C., Shvero J., Levy R., Segal K., Anaplastic carcinoma of the thyroid European Journal of Surgical Oncology 1993 19 6 511 516 (Pubitemid 24024594)
6. Haigh P. I., Ituarte P. H., Wu H. S., Treseler P. A., Posner M. D., Quivey J. M., Duh Q. Y., Clark O. H., Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival Cancer 2001 91 12 2335 2342 (Pubitemid 32552820)
7. Hundahl S. A., Cady B., Cunningham M. P., Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study Cancer 2000 89 1 202 217 (Pubitemid 30451292)
8. Hundahl S. A., Fleming I. D., Fremgen A. M., Menck H. R., A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 19851995 Cancer 1998 83 12 2638 2648 (Pubitemid 29019586)
9. Jereb B., Stjernsward J., Lowhagen T., Anaplastic giant cell carcinoma of the thyroid. A study of treatment and prognosis Cancer 1975 35 5 1293 1295
10. Junor E. J., Paul J., Reed N. S., Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy European Journal of Surgical Oncology 1992 18 2 83 88
11. Kebebew E., Greenspan F. S., Clark O. H., Woeber K. A., McMillan A., Anaplastic thyroid carcinoma: treatment outcome and prognostic factors Cancer 2005 103 7 1330 1335 (Pubitemid 40410726)
12. Kim J. H., Leeper R. D., Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy Cancer 1987 60 10 2372 2375 (Pubitemid 17157239)
13. Kim J. H., Leeper R. D., Combination adriamycin and radiation therapy for locally advanced carcinoma of the thyroid gland International Journal of Radiation Oncology Biology Physics 1983 9 4 565 567 (Pubitemid 13097095)
14. Kurebayashi J., Okubo S., Yamamoto Y., Ikeda M., Tanaka K., Otsuki T., Sonoo H., Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells Cancer Chemotherapy and Pharmacology 2006 58 4 460 470 (Pubitemid 43999794)
15. Lam K. Y., Lo C. Y., Chan K. W., Wan K. Y., Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21 Annals of Surgery 2000 231 3 329 338
16. Mitchell G., Huddart R., Harmer C., Phase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma Radiotherapy and Oncology 1999 50 1 33 38 (Pubitemid 29136736)
17. Nel C. J., van Heerden J. A., Goellner J. R., Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases Mayo Clinic Proceedings 1985 60 1 51 58 (Pubitemid 15199625)
18. Nilsson O., Lindeberg J., Zedenius J., Ekman E., Tennvall J., Blomgren H., Grimelius L., Lundell G., Wallin G., Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period World Journal of Surgery 1998 22 7 725 730 (Pubitemid 28277869)
19. Schlumberger M., Parmentier C., Delisle M. J., Couette J. E., Droz J. P., Sarrazin D., Combination therapy for anaplastic giant cell thyroid carcinoma Cancer 1991 67 3 564 566
20. Simpson W. J., Anaplastic thyroid carcinoma: a new approach Canadian Journal of Surgery 1980 23 1 25 27 (Pubitemid 10159897)
21. Spires J. R., Schwartz M. R., Miller R. H., Anaplastic thyroid carcinoma. Association with differentiated thyroid cancer Archives of Otolaryngology 1988 114 1 40 44 (Pubitemid 18031595)
22. Tallroth E., Wallin G., Lundell G., Lowhagen T., Einhorn J., Multimodality treatment in anaplastic giant cell thyroid carcinoma Cancer 1987 60 7 1428 1431 (Pubitemid 17140988)
23. Tan R. K., Finley R. K. III, Driscoll D., Bakamjian V., Hicks W. L. Jr., Shedd D. P., Anaplastic carcinoma of the thyroid: a 24-year experience Head Neck 1995 17 1 41 48
24. Venkatesh Y. S., Ordonez N. G., Schultz P. N., Hickey R. C., Goepfert H., Samaan N. A., Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases Cancer 1990 66 2 321 330 (Pubitemid 20205915)
25. Voutilainen P. E., Multanen M., Haapiainen R. K., Leppaniemi A. K., Sivula A. H., Anaplastic thyroid carcinoma survival World Journal of Surgery 1999 23 9 975 978
26. Are C., Shaha A. R., Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches Annals of Surgical Oncology 2006 13 4 453 464
27. McIver B., Hay I. D., Giuffrida D. F., Dvorak C. E., Grant C. S., Thompson G. B., Van Heerden J. A., Goellner J. R., Anaplastic thyroid carcinoma: a 50-year experience at a single institution Surgery 2001 130 6 1028 1034 (Pubitemid 34014569)
28. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M. J., Cancer statistics, 2007 CA: A Cancer Journal for Clinicians 2007 57 1 43 66 (Pubitemid 46148091)
29. Davies L., Welch H. G., Increasing incidence of thyroid cancer in the United States, 19732002 Journal of the American Medical Association 2006 295 18 2164 2167
30. Swaak-Kragten A. T., de Wilt J. H., Schmitz P. I., Bontenbal M., Levendag P. C., Multimodality treatment for anaplastic thyroid carcinomatreatment outcome in 75 patients Radiotherapy and Oncology 2009 92 1 100 104
31. Vrbic S., Pejcic I., Vrbic M., Filipovic S., Therapy of stage IV B anaplastic thyroid carcinoma: single institution experience Journal of Balkan Union of Oncology 2009 14 1 41 44
32. Yau T., Lo C. Y., Epstein R. J., Lam A. K., Wan K. Y., Lang B. H., Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy Annals of Surgical Oncology 2008 15 9 2500 2505
33. Lim S., Lee N., Fury M. G., Doxorubucin and concurrent radiotherapy for anaplastic thyroid cancer: we need to do better Journal of Clinical Oncology 2007 25 18S, abstract 735
34. Lee Y., Jung J., Hwang H., Im Y., Multimodal therapeutic approach in anaplastic thyroid cancer Journal of Clinical Oncology 2006 24, supplement, article 15533 18S
35. Wang Y., Tsang R., Asa S., Dickson B., Arenovich T., Brierley J., Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens Cancer 2006 107 8 1786 1792 (Pubitemid 44582947)
36. Veness M. J., Porter G. S., Morgan G. J., Anaplastic thyroid carcinoma: dismal outcome despite current treatment approach Australian and New Zealand Journal of Surgery 2004 74 7 559 562 (Pubitemid 39006078)
37. Besic N., Auersperg M., Us-Krasovec M., Golouh R., Frkovic-Grazio S., Vodnik A., Effect of primary treatment on survival in anaplastic thyroid carcinoma European Journal of Surgical Oncology 2001 27 3 260 264 (Pubitemid 32621750)
38. Sugino K., Ito K., Mimura T., Nagahama M., Fukunari N., Kubo A., Iwasaki H., Ito K., The important role of operations in the management of anaplastic thyroid carcinoma Surgery 2002 131 3 245 248 (Pubitemid 34229776)
39. Heron D. E., Karimpour S., Grigsby P. W., Anaplastic thyroid carcinoma: comparison of conventional radiotherapy and hyperfractionation chemoradiotherapy in two groups American Journal of Clinical Oncology 2002 25 5 442 446 (Pubitemid 35154945)
40. Tennvall J., Lundell G., Hallquist A., Wahlberg P., Wallin G., Tibblin S., Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group Cancer 1994 74 4 1348 1354 (Pubitemid 24301791)
41. Levendag P. C., De Porre P. M., van Putten W. L., Anaplastic carcinoma of the thyroid gland treated by radiation therapy International Journal of Radiation Oncology Biology Physics 1993 26 1 125 128 (Pubitemid 23137897)
42. Agrawal S., Rao R. S., Parikh D. M., Parikh H. K., Borges A. M., Sampat M. B., Histologic trends in thyroid cancer 19691993: a clinico-pathologic analysis of the relative proportion of anaplastic carcinoma of the thyroid Journal of Surgical Oncology 1996 63 4 251 255 (Pubitemid 27009242)
43. Lampertico P., Anaplastic (sarcomatoid) carcinoma of the thyroid gland Seminars in Diagnostic Pathology 1993 10 2 159 168 (Pubitemid 23204899)
44. Trimboli P., Ulisse S., Graziano F. M., Marzullo A., Ruggieri M., Calvanese A., Piccirilli F., Cavaliere R., Fumarola A., D'Armiento M., Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective study of 500 cases diagnosed over 20 years Thyroid 2006 16 11 1151 1155 (Pubitemid 44864490)
45. Ezaki H., Ebihara S., Fujimoto Y., Iida F., Ito K., Kuma K., Izuo M., Makiuchi M., Oyamada H., Matoba N., Yagawa K. I., Analysis of thyroid carcinoma based on material registered in Japan during 19771986 with special reference to predominance of papillary type Cancer 1992 70 4 808 814
46. Kitagawa W., Shimizu K., Akasu H., Tanaka S., Endocrine surgery. The ninth report: the latest data on and clinical characteristics of the epidemiology of thyroid carcinoma Journal of Nippon Medical School 2003 70 1 57 61 (Pubitemid 36305755)
47. Ratnatunga P. C., Amarasinghe S. C., Ratnatunga N. V., Changing patterns of thyroid cancer in Sri Lanka. Has the iodination programme helped? The Ceylon Medical Journal 2003 48 4 125 128
48. Reynolds R. M., Weir J., Stockton D. L., Brewster D. H., Sandeep T. C., Strachan M. W., Changing trends in incidence and mortality of thyroid cancer in Scotland Clinical Endocrinology 2005 62 2 156 162 (Pubitemid 40203909)
49. Bakiri F., Djemli F. K., Mokrane L. A., Djidel F. K., The relative roles of endemic goiter and socioeconomic development status in the prognosis of thyroid carcinoma Cancer 1998 82 6 1146 1153 (Pubitemid 28136530)
50. Besic N., Hocevar M., Zgajnar J., Lower incidence of anaplastic carcinoma after higher iodination of salt in slovenia Thyroid 2010 20 6 623 626
51. Chen J., Tward J. D., Shrieve D. C., Hitchcock Y. J., Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 19832002 American Journal of Clinical Oncology 2008 31 5 460 464
52. Gilliland F. D., Hunt W. C., Morris D. M., Key C. R., Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 19731991 Cancer 1997 79 3 564 573 (Pubitemid 27051783)
53. Lo C. Y., Lam K. Y., Wan K. Y., Anaplastic carcinoma of the thyroid The American Journal of Surgery 1999 177 4 337 339
54. Kim T. Y., Kim K. W., Jung T. S., Kim J. M., Kim S. W., Chung K. W., Eun Y. K., Gong G., Young L. O., Soo Y. C., Ka H. Y., Won B. K., Do J. P., Jae H. C., Bo Y. C., Shong Y. K., Prognostic factors for korean patients with anaplastic thyroid carcinoma Head Neck 2007 29 8 765 772 (Pubitemid 47265532)
55. Roche B., Larroumets G., Dejax C., Kwiatkowsi F., Desbiez F., Thieblot P., Tauveron I., Epidemiology, clinical presentation, treatment and prognosis of a regional series of 26 anaplastic thyroid carcinomas (ATC). Comparison with the literature Annales d'Endocrinologie 2010 71 1 38 45
56. Sugitani I., Kasai N., Fujimoto Y., Yanagisawa A., Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid World Journal of Surgery 2001 25 5 617 622 (Pubitemid 32441436)
57. Lee N., Puri D. R., Blanco A. I., Chao K. S., Intensity-modulated radiation therapy in head and neck cancers: an update Head Neck 2007 29 4 387 400 (Pubitemid 46623504)
58. Rosenbluth B. D., Serrano V., Happersett L., Shaha A. R., Tuttle R. M., Narayana A., Wolden S. L., Rosenzweig K. E., Chong L. M., Lee N. Y., Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer International Journal of Radiation Oncology Biology Physics 2005 63 5 1419 1426 (Pubitemid 41628037)
59. Wong C. S., Van Dyk J., Simpson W. J., Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma Radiotherapy and Oncology 1991 20 1 3 9
60. Tennvall J., Tallroth E., el Hassan A., Lundell G., Akerman M., Biorklund A., Blomgren H., Lowhagen T., Wallin G., Anaplastic thyroid carcinoma. Doxorubicin, hyperfractionated radiotherapy and surgery Acta Oncologica 1990 29 8 1025 1028
61. Sosa J. A., Elisei R., Jarzab B., Randomized phase 2/3 trial of a tunor vascular disrupting agent, fosbertubulin (CA4P), with carboplatin(C), and paclitaxel(P) in anaplastic thyroid cancer(ATC): interim safety and efficacy results of the FACT trial. Milan, Italy, 2010
62. Troch M., Koperek O., Scheuba C., High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel Journal of Clinical Endocrinology Metabolism 2010 95 9 E54 E57
63. Mooney C. J., Nagaiah G., Fu P., Wasman J. K., Cooney M. M., Savvides P. S., Bokar J. A., Dowlati A., Wang D., Agarwala S. S., Flick S. M., Hartman P. H., Ortiz J. D., Lavertu P. N., Remick S. C., A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome Thyroid 2009 19 3 233 240
64. Nagaiah G., Fu P., Wasman J. K., Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC) Journal of Clinical Oncology 2009 27 15S, supplement. abstract 6058
65. Koussis H., Scola A., Tonello S., Multimodality therapeutic approach in anaplastic thyroid cancer (ATC): study of 56 patients Journal of Clinical Oncology 2006 24 18S, supplement. ASCO Annual Meeting Proceedings Part I. Vol. 24
66. Wallin G., Lundell G., Tennvall J., Anaplastic giant cell thyroid carcinoma Scandinavian Journal of Surgery 2004 93 4 272 277 (Pubitemid 40095953)
67. De Crevoisier R., Baudin E., Bachelot A., Leboulleux S., Travagli J. P., Caillou B., Schlumberger M., Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy International Journal of Radiation Oncology Biology Physics 2004 60 4 1137 1143 (Pubitemid 39440799)
68. Mitchel F. W., Suzanne L. W., Andrew G. H., Hyperfractionated radiation therapy and adriamycin for anaplastic thyroid cancer Proceedings American Society of Clinical Oncology 2002 21, abstract 931
69. Ain K. B., Egorin M. J., DeSimone P. A., Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group Thyroid 2000 10 7 587 594 (Pubitemid 30670619)
70. Busnardo B., Daniele O., Pelizzo M. R., Mazzarotto R., Nacamulli D., DeVido D., Mian C., Girelli M. E., A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients Journal of Endocrinological Investigation 2000 23 11 755 761 (Pubitemid 32041056)
71. Bhatia A., Rao A., Ang K. K., Garden A. S., Morrison W. H., Rosenthal D. I., Evans D. B., Clayman G., Sherman S. I., Schwartz D. L., Anaplastic thyroid cancer: clinical outcomes with conformal radiotherapy Head Neck 2010 32 7 829 836
72. Tennvall J., Lundell G., Wahlberg P., Bergenfelz A., Grimelius L., kerman M., Hjelm Skog A. L., Wallin G., Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery British Journal of Cancer 2002 86 12 1848 1853
73. Lehnert M., Clinical multidrug resistance in cancer: a multifactorial problem European Journal of Cancer 1996 32 6 912 920
74. Satake S., Sugawara I., Watanabe M., Takami H., Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines Cancer Letters 1997 116 1 33 39 (Pubitemid 27226147)
75. Ahuja S., Ernst H., Chemotherapy of thyroid carcinoma Journal of Endocrinological Investigation 1987 10 3 303 310 (Pubitemid 17097636)
76. Shimaoka K., Schoenfeld D. A., DeWys W. D., A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma Cancer 1985 56 9 2155 2160 (Pubitemid 16236586)
77. Catalano M. G., Fortunati N., Pugliese M., Poli R., Bosco O., Mastrocola R., Aragno M., Boccuzzi G., Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells Journal of Endocrinology 2006 191 2 465 472 (Pubitemid 44830622)
78. Higashiyama T., Ito Y., Hirokawa M., Fukushima M., Uruno T., Miya A., Matsuzuka F., Miyauchi A., Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma Thyroid 2010 20 1 7 14
79. Kawada K., Kitagawa K., Kamei S., Inada M., Mitsuma A., Sawaki M., Kikumori T., Fujimoto Y., Arima H., Imai T., Ando Y., The feasibility study of docetaxel in patients with anaplastic thyroid cancer Japanese Journal of Clinical Oncology 2010 40 6 596 599
80. Yeung S. C., Xu G., Pan J., Christgen M., Bamiagis A., Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells Cancer Research 2000 60 3 650 656 (Pubitemid 30094563)
81. Voigt W., Kegel T., Weiss M., Mueller T., Simon H., Schmoll H. J., Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma Journal of Cancer Research and Clinical Oncology 2005 131 9 585 590 (Pubitemid 41558551)
82. Sokal M., Harmer C. L., Chemotherapy for anaplastic carcinoma of the thyroid Clinical Oncology 1978 4 1 3 10 (Pubitemid 8304863)
83. Blagosklonny M. V., Giannakakou P., Wojtowicz M., Romanova L. Y., Ain K. B., Bates S. E., Fojo T., Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells Journal of Clinical Endocrinology Metabolism 1998 83 7 2516 2522 (Pubitemid 28503056)
84. Kotchetkov R., Cinatl J., Krivtchik A. A., Vogel J. U., Matousek J., Pouckova P., Kornhuber B., Schwabe D., Cinatl J., Selective activity of BS-RNase against anaplastic thyroid cancer Anticancer Research 2001 21 2A 1035 1042 (Pubitemid 32494204)
85. Franzen A., Heldin N. E., BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1) Biochemical and Biophysical Research Communications 2001 285 3 773 781 (Pubitemid 32924836)
86. Schiff B. A., McMurphy A. B., Jasser S. A., Younes M. N., Doan D., Yigitbasi O. G., Kim S., Zhou GE., Mandal M., Bekele B. N., Holsinger F. C., Sherman S. I., Yeung S. C., El-Naggar A. K., Myers J. N., Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer Clinical Cancer Research 2004 10 24 8594 8602 (Pubitemid 40053427)
87. Kim S., Prichard C. N., Younes M. N., Yazici Y. D., Jasser S. A., Bekele B. N., Myers J. N., Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice Clinical Cancer Research 2006 12 2 600 607 (Pubitemid 43166155)
88. Kim S., Schiff B. A., Yigitbasi O. G., Doan D., Jasser S. A., Bekele B. N., Mandal M., Myers J. N., Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788 Molecular Cancer Therapeutics 2005 4 4 632 640 (Pubitemid 40601845)
89. Furuya F., Shimura H., Suzuki H., Taki K., Ohta K., Haraguchi K., Onaya T., Endo T., Kobayashi T., Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin Endocrinology 2004 145 6 2865 2875 (Pubitemid 38686236)
90. Imanishi R., Ohtsuru A., Iwamatsu M., Iioka T., Namba H., Seto S., Yano K., Yamashita S., A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy Journal of Clinical Endocrinology Metabolism 2002 87 10 4821 4824 (Pubitemid 35247082)
91. Mitsiades C. S., Poulaki V., McMullan C., Novel histone deacetylase inhibitors in the treatment of thyroid cancer Clinical Cancer Research 2005 11 10 3958 3965 (Pubitemid 40685618)
92. Alfano R. W., Leppla S. H., Liu S., Bugge T. H., Ortiz J. M., Lairmore T. C., Duesbery N. S., Mitchell I. C., Nwariaku F., Frankel A. E., Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma Molecular Cancer Therapeutics 2010 9 1 190 201
93. Podtcheko A., Ohtsuru A., Namba H., Saenko V., Starenki D., Palona I., Sedliarou I., Rogounovitch T., Yamashita S., Inhibition of ABL tyrosine kinase potentiates radiation-induced terminal growth arrest in anaplastic thyroid cancer cells Radiation Research 2006 165 1 35 42 (Pubitemid 43023322)
94. Podtcheko A., Ohtsuru A., Tsuda S., Namba H., Saenko V., Nakashima M., Mitsutake N., Kanda S., Kurebayashi J., Yamashita S., The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells Journal of Clinical Endocrinology Metabolism 2003 88 4 1889 1896 (Pubitemid 36623419)
95. Dziba J. M., Ain K. B., Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro Journal of Clinical Endocrinology Metabolism 2004 89 5 2127 2135 (Pubitemid 38619841)
96. Kim S., Yazici Y. D., Calzada G., Wang Z. Y., Younes M. N., Jasser S. A., El-Naggar A. K., Myers J. N., Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice Molecular Cancer Therapeutics 2007 6 6 1785 1792 (Pubitemid 46954055)
97. Gupta-Abramson V., Troxel A. B., Nellore A., Puttaswamy K., Redlinger M., Ransone K., Mandel S. J., Flaherty K. T., Loevner L. A., O'Dwyer P. J., Brose M. S., Phase II trial of sorafenib in advanced thyroid cancer Journal of Clinical Oncology 2008 26 29 4714 4719
98. Inai T., Mancuso M., Hashizume H., Baffert F., Haskell A., Baluk P., Hu-Lowe D. D., Shalinsky D. R., Thurston G., Yancopoulos G. D., M D. M., Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts American Journal of Pathology 2004 165 1 35 52 (Pubitemid 38821812)
99. Cohen E. E., Rosen L. S., Vokes E. E., Kies M. S., Forastiere A. A., Worden F. P., Kane M. A., Sherman E., Kim S., Bycott P., Tortorici M., Shalinsky D. R., Liau K. F., Cohen R. B., Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study Journal of Clinical Oncology 2008 26 29 4708 4713
100. Dark G. G., Hill S. A., Prise V. E., Tozer G. M., Pettit G. R., Chaplin D. J., Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature Cancer Research 1997 57 10 1829 1834 (Pubitemid 27209705)
101. Vincent L., Kermani P., Young L. M., Cheng J., Zhang F., Shido K., Lam G., Bompais-Vincent H., Zhu Z., Hicklin D. J., Bohlen P., Chaplin D. J., May C., Raf S. II, Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling Journal of Clinical Investigation 2005 115 11 2992 3006 (Pubitemid 41567565)
102. Pettit G. R., Singh S. B., Hamel E., Lin C. M., Alberts D. S., Garcia-Kendall D., Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 Experientia 1989 45 2 209 211 (Pubitemid 19062390)
103. Grosios K., Loadman P. M., Swaine D. J., Pettit G. R., Bibby M. C., Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma Anticancer Research 2000 20 1 229 233 (Pubitemid 30189759)
104. Murata R., Siemann D. W., Overgaard J., Horsman M. R., Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors Radiotherapy and Oncology 2001 60 2 155 161 (Pubitemid 32601968)
105. Barzon L., Pacenti M., Taccaliti A., Franchin E., Bruglia M., Boscaro M., Pal G., A pilot study of combined suicide/cytokine gene therapy in two patients with end-stage anaplastic thyroid carcinoma Journal of Clinical Endocrinology Metabolism 2005 90 5 2831 2834 (Pubitemid 40686332)
106. Pathak M. K., Yi T., Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines Journal of Immunology 2001 167 6 3391 3397 (Pubitemid 32852583)
107. Lin S. F., Yu Z., Riedl C., Woo Y., Zhang Q., Yu Y. A., Timiryasova T., Chen N., Shah J. P., Szalay A. A., Fong Y., Wong R. J., Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus Surgery 2007 142 6 976 983 (Pubitemid 350193250)
108. Yu G. P., Li J. C., Branovan D., McCormick S., Schantz S. P., Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups Thyroid 2010 20 5 465 473